Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
Papillomavirus Infections
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 700 (planned)
- Started
- Mar 15, 2021
- Main results expected
- Oct 23, 2029
- Fully finished
- Oct 23, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Geometric Mean Titers of Anti-Human Papilloma Virus Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 as Measured by Competitive Luminex Immunoassay
Measured over: 4 weeks post last vaccination (Up to ~Month 61)
Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event
Measured over: Up to 5 days post vaccination
Percentage of Participants With at Least 1 Systemic Adverse Event
Measured over: Up to 15 days post vaccination
Percentage of Participants With at Least 1 Serious Vaccine-Related Adverse Event
Measured over: Entire study period (Up to ~Month 96)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04708041 · record last updated 2025-04-20 · checked 2026-11-09 15:47 UTC